华夏小葱制剂对脂肪肝大鼠的防治作用

Preparation of Chinese Allium fistulosum Linn in the prevention and treatment of rats with fatty liver disease

目的:探讨华夏小葱制剂对大鼠脂肪肝的防治作用及其机制.方法:60只SD大鼠随机平均分为6个组:空白对照组,模型对照组,华夏小葱制剂低、中、高剂量组以及东宝肝泰片组.除空白对照组外,其他组用高脂饮食及酒精水喂养,并结合皮下注射小剂量四氯化碳色拉油溶液建立大鼠脂肪肝模型.华夏小葱制剂低、中、高剂量组及东宝肝泰片组分别给予相应剂量的华夏小葱制剂0.06,0.12,0.24g/kg或东宝肝泰片混悬液0.7g/kg.8wk后计算肝脏指数(肝湿质量/体质量),取肝左叶作组织病理学检查,全自动生化分析仪测定总胆固醇(TC)、甘油三酯(TG)等指标,放射免疫法测定血浆内皮素(ET-1)含量,RT-PCR测定肿瘤坏死因子-α(TNF-α)mRNA的表达,Western blot检测核转录因子-kB(NF-kB)p65蛋白的表达.结果:模型对照组肝指数、TC、TG、ET、TNF-αmRNA及NF-kB值(分别是2.33%±0.08%,1.39±0.31mmol/L,0.48±0.08mmol/L,138.67±21.84ng/L,0.47±0.01,110.67±12.90)显著高于空白对照组(P<0.01);华夏小葱低、中、高剂量组及东宝肝泰片组肝指数、TC、TG、ET-1、TNF-αmRNA、NF-kBp65值(肝指数:2.59%±0.12%,2.55%±0.19%,2.65%±0.25%,2.57%±0.16%,P<0.01;TC:1.67±0.31,1.65±0.17,1.69±0.29,1.52±0.31mmol/L,P<0.05orP<0.01;TG:0.65±0.23,0.60±0.29,0.55±0.17,0.61±0.27mmol/L,P<0.05orP<0.01;ET-1:149.39±17.82,136.91±22.48,130.52±24.93,154.45±18.46ng/L,P<0.05orP<0.01;TNF-αmRNA:0.79±0.01,0.73±0.03,0.64±0.05,0.71±0.02,P<0.01或无显著性差异;NF-kBp65:158.67±8.08,141.33±9.29,115.67±14.05,118.00±9.85,P<0.05orP<0.01)低于模型对照组(分别是3.45%±0.20%,2.03±0.38mmol/L,1.18±0.57mmol/L,180.22±9.80ng/L,0.84±0.04,180.33±8.39).结论:华夏小葱制剂对实验性大鼠脂肪肝具有较好的防治作用,其机制可能与降低NF-kB的激活、减少ET-1和TNF-α的损伤有关.

AIM： To investigate the preventive and therapeutic effect of preparation of Chinese Allium fistulosum Linn （PCAL） on the rats with fatty liver disease （FLD） and its related mechanism. METHODS： Sixty Sprague Dawley rats were randomly and averagely divided into group A, B, C, D, E and F. High-fat diet, ethanol, and carbon tetrachloride （CCl4） were used to induce the model of FLD in all the rats except those in group A, and the rats in controls. Then the rats group A served as blank in group C, D, E and F were treated with low-, middle-, and high-dose PCAL （0.06, 0.12, 0.24 g/kg, repectively）, and Dongbao Gantai （DBGT, 0.7 g/kg）, respectively. All the animals were sacrificed after 8 weeks. Liver index （liver/body weight ratio） was calculated, and the levels of plasma total cholesterol （TC） and triglyceride （TG） were determined by automatic biochemical analyzer. Plasma endothelin-1 （ET-1） was assayed by radioimmunoassay. Reverse transcription-polymerase chain reaction （RT-PCR） and Western blotting were used to measure the expression of tumor necrosis factor-α （TNF-α） mRNA and nuclear transcription factor-κB （NF-κB） in liver tissues, respectively. RESULTS： Liver index, the levels of plasma TC, TG, ET-1, the expression of TNF-α mRNA and NF-κB p65 protein were significantly higher in group B that those in group A （3.45% ± 0.20% vs 2.33% ± 0.08%; 2.03 ± 0.38 mmol/L vs 1.39 ± 0.31 mmol/L; 1.18 ± 0.57 mmol/L vs 0.48 ± 0.08 mmol/L; 180.22 ± 9.80 ng/L vs 138.67 ± 21.84 ng/L; 0.84 ± 0.04 vs 0.47 ± 0.01; 180.33 ± 8.39 vs 110.67 ± 12.90; all P 〈 0.01）. However, the above indexes were obviously decreased in group C, D, E and F （liver index： 2.59% ± 0.12%, 2.55% ± 0.19%, 2.65% ± 0.25%, 2.57% ± 0.16%, P 〈 0.01; TC： 1.67 ± 0.31, 1.65 ± 0.17, 1.69 ± 0.29, 1.52 ± 0.31 mmol/L, P 〈 0.05 or P 〈 0.01; TG： 0.65 ± 0.23, 0.60 ± 0.29, 0.55 ± 0.17, 0.61 ± 0.27 mmol/L, P 〈 0.05 or P 〈 0.01; ET-1： 149.39 ± 17.82, 136.91 ± 22.48, 130.52 ± 24.93, 154.45 ± 18.46 ng/L P 〈 0.05 or P 〈 0.01; TNF-α mRNA： 0.79 ± 0.01, 0.73 ± 0.03, 0.64 ± 0.05, 0.71 ± 0.02, P 〈 0.01 or no significance; NF-κB p65：158.67 ± 8.08, 141.33 ± 9.29, 115.67 ± 14.05, 118.00 ± 9.85, P 〈 0.05 or P 〈 0.01） in comparison with those in group B. CONCLUSION： PCAL is effective in the prevention and therapy of FLD rats, and the mechanism may be related to the reduction of NF-κB activity in liver tissues and alleviation of ET-1- and TNF-α-induced tissue impairment.